Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

F. Palandri, G.A. Palumbo, E. Abruzzese, A. Iurlo, N. Polverelli, E. Elli, M. Bonifacio, M. Bergamaschi, B. Martino, M. Tiribelli, G. Benevolo, A. Tieghi, N. Sgherza, A. Isidori, G. Binotto, M. Crugnola, F. Heidel, F. Cavazzini, C. Bosi, G. AuteriD. Cattaneo, R. Foà, R.M. Lemoli, A. Cuneo, M. Krampera, D. Bartoletti, M. Cavo, N. Vianelli, M. Breccia, R. Latagliata

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)418-423
JournalHematological Oncology
Volume37
Issue number4
DOIs
Publication statusPublished - 2019

Keywords

  • EARLY PMF
  • MYELOFIBROSIS
  • OVERT PMF
  • RUXOLITINIB

Cite this

Palandri, F., Palumbo, G. A., Abruzzese, E., Iurlo, A., Polverelli, N., Elli, E., Bonifacio, M., Bergamaschi, M., Martino, B., Tiribelli, M., Benevolo, G., Tieghi, A., Sgherza, N., Isidori, A., Binotto, G., Crugnola, M., Heidel, F., Cavazzini, F., Bosi, C., ... Latagliata, R. (2019). Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematological Oncology, 37(4), 418-423. https://doi.org/10.1002/hon.2619